[Reading level: C1 – Advanced]
A Chinese scientist claims to have edited the genomes of twin baby girls.
Humanity’s power to control the four-letter code of life has advanced by leaps and bounds. A new gene-editing technology called CRISPR-CAS9, which was not discovered until 2012, has been the subject of particular excitement. It allows DNA to be edited easily, raising hopes that it could eventually be used to relieve human suffering. Recently, however, CRISPR has caused more unease than optimism, because of claims by a Chinese scientist that he edited the genomes of twin girls when they were embryos, as part of IVF treatment.
He Jiankui, of the Southern University of Science and Technology, in Shenzhen – which was not involved in the work – says he edited a gene, CCR5, that allows HIV to infect human cells. Mr He claims to have created one baby resistant to HIV infection, and a twin who is not. (Another woman is apparently carrying an edited embryo.) If reproductive cells were affected, any such modifications will be passed on to subsequent generations. There is still uncertainty over what Mr He has done. But it is just a matter of time before someone, somewhere, edits human embryos that are grown into babies. Governments and regulators need to pay heed.
Presume that Mr He’s assertions are truthful, one day it may make sense to edit an embryo – to cure genetic diseases, say. That day has not arrived. The technology is so new that the risks to human subjects cannot possibly justify the benefits. Scientists do not fully understand the scope of the unintended damage CRISPR does to DNA elsewhere in the genome or how deactivating CCR5 might leave you vulnerable to other diseases (it may, for instance, make death from flu more likely).
Mr He’s work appears to have had the scantiest oversight and a vice-minister says it violates regulations. It seems likely that Mr He himself was largely responsible for deciding whether his human experiment was worth the risks. It is not clear that the babies’ parents gave their informed consent.
Nor did the procedure fulfill any unmet medical need. For the child whose genome was edited to confer resistance, the claimed benefit is protection from a virus that she may never encounter (although her father is HIV-positive, his sperm were washed to prevent infection during fertilization). If the reports are correct, the second child has been exposed to the potential risks of an edited genome but can still be infected by HIV.
The idea that one scientist could make the leap towards editing reproductive cells has been condemned, but it has not been ruled out. Even if Mr He turns out to be a fraud, others have the means, the motive and the opportunity to do similar work. CRISPR is not a complex technology. That leads to two responses.
The first is practical: better oversight of places such as fertility clinics, where back-room genome-tinkerers may lurk. That applies not just in China, where Mr He has attracted vocal condemnation, but also in America, where IVF clinics could use greater regulatory scrutiny.
The second is proper debate about when gene-editing is warranted. Editing the unhealthy cells of those suffering from genetic diseases such as Duchenne’s muscular dystrophy and cystic fibrosis will alleviate their suffering. It is less clear when it is necessary to edit embryos, but Mr He’s experiment obviously fails the test. Fertility treatments already screen embryos for unwanted genes.
It may even be that editing will one day be used on embryos to enhance genomes (to make people cleverer, say), rather than to cure disease. But that requires regulators, policymakers, scientists and civil society to think through deep ethical questions. Work is already under way to develop principles for editing reproductive cells. Earlier this year the Nuffield Council on Bioethics, a think-tank in Britain, outlined two: that the changes brought about by gene-editing should not increase “disadvantage, discrimination or division in society” and that such changes should not harm the welfare of the future person. Such debate was always going to be needed. Now it is urgent.
by leaps and bounds (idiom): một cách nhanh chóng
relieve /rɪˈliːv/ [C2] (v): giảm bớt
unease /ʌnˈiːz/ (n): sự bất mãn, sự không hài lòng, sự lo lắng
embryo /ˈem.bri.əʊ/ (n): phôi thai
resistant to sth /rɪˈzɪs.tənt/ (adj): khả năng kháng cái gì
apparently /əˈpær.ənt.li/ [B2] (adv): rõ ràng
reproductive cell (n): tế bào sinh sản
pay heed /hiːd/ (v): chú ý
presume /prɪˈzjuːm/ [C1] (v): giả sử
assertion /əˈsɜː.ʃən/ (n): khẳng định
deactivate /ˌdiˈæk.tɪ.veɪt/ (v): vô hiệu hóa
vulnerable to sth /ˈvʌn.rə.bəl/ [C2] (adj): dễ bị
scant /skænt/ (adj): ít ỏi
oversight /ˈəʊ.və.saɪt/ (n): giám sát
consent /kənˈsent/ [C1] (n): sự đồng thuận
confer /kənˈfɜːr/ (v): mang lại, trao
sperm /spɜːm/ (n): tinh trùng
fertilization /ˌfɜː.tɪ.laɪˈzeɪ.ʃən/ (n): thụ tinh
be exposed to sth /ɪkˈspəʊzd/ (v): bị đối mặt với cái gì
make a leap (v): tạo ra bước nhảy vọt
condemn /kənˈdem/ [C2] (v): lên án
rule out (v): loại trừ, ngăn chặn
fraud /frɔːd/ [C2] (n): kẻ lừa đảo
motive /ˈməʊ.tɪv/ [B2] (n): động cơ
tinker /ˈtɪŋ.kər/ (v): mày mò
lurk /lɜːk/ (v): ẩn nấp
scrutiny /ˈskruː.tɪ.ni/ [C2] (n): cân nhắc kỹ lưỡng
alleviate /əˈliː.vi.eɪt/ (v): làm giảm bớt
screen /skriːn/ (v): sàng lọc
urgent /ˈɜː.dʒənt/ [B1] (adj): khẩn cấp, cấp bách
ỦNG HỘ READ TO LEAD!
Chào bạn! Có thể bạn chưa biết, Read to Lead là một trang giáo dục phi lợi nhuận với mục đích góp phần phát triển cộng đồng người học tiếng Anh tại Việt Nam. Chúng tôi không yêu cầu người đọc phải trả bất kỳ chi phí nào để sử dụng các sản phẩm chất lượng của mình để mọi người đều có cơ hội học tập tốt hơn. Tuy nhiên, nếu bạn có thể, chúng tôi mong nhận được sự hỗ trợ tài chính từ bạn để duy trì hoạt động của trang và phát triển các sản phẩm mới.
Bạn có thể ủng hộ chúng tôi qua 1 trong 2 cách dưới đây.
– Cách 1: Chuyển tiền qua tài khoản Momo.
Số điện thoại 0886.630.599 (Chủ tài khoản: Nguyễn Thị Phương Thảo)
Nội dung chuyển tiền: Ủng hộ Read to Lead
– Cách 2: Chuyển tiền qua tài khoản ngân hàng.
Ngân hàng VIB chi nhánh Hải Phòng
Số tài khoản: 071704060005623 (Chủ tài khoản: Nguyễn Thị Phương Thảo)
Nội dung chuyển tiền: Ủng hộ Read to Lead